Table 4.
Concordance between Molecular Diagnostics and [18F]FDG-PET/CT
| MD | [18F]FDG-PET/CT | Histopathology |
ROM, % [CI] | |
|---|---|---|---|---|
| Malignant/borderline | Benign | |||
| MD on cytology (n = 115), assuming nodules under active surveillance are benign (a priori ROM 26%) | ||||
| MD and [18F]FDG-PET/CT concordant (n = 72) | ||||
| − | − | 1 | 29 | 3 [0–17] |
| + | + | 22 | 20 | 52 [36–68] |
| MD and [18F]FDG-PET/CT discordant (n = 43) | ||||
| + | − | 1 | 6 | 14 [0–58] |
| − | + | 6 | 30 | 17 [6–33] |
| MD on cytology and histopathology (n = 130), assuming nodules under active surveillance are benign (a priori ROM 26%) | ||||
| MD and [18F]FDG-PET/CT concordant (n = 82) | ||||
| − | − | 0 | 30 | 0 [0–12] |
| + | + | 27 | 25 | 52 [38–66] |
| MD and [18F]FDG-PET/CT discordant (n = 48) | ||||
| + | − | 2 | 7 | 22 [3–60] |
| − | + | 5 | 34 | 13 [4–27] |